Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Interactive workshop with Pfizer gives Oxford’s Industry Fellows the opportunity to put into action the Drug Discovery & Development Process

Recently Industry Fellows from across the Medical Sciences Division attended a workshop delivered by Dr Nick Clarke, Head of UK Academic Partnerships at the pharmaceutical company Pfizer. Organised by the Medical Sciences Business Development Team, the interactive workshop session involved group discussions and simulations of the entire decision making process involved in drug discovery and development.

Participants were invited to work as a team to bring a drug from pre-clinical research through to final approval from the Food and Drug Administration (FDA). The 3D interactive session used a computer programme to simulate the entire spectrum of R&D process based decisions, and the group of industry fellows had to work together to advance the drug candidate forward (or not) in the space of 4 hours. 

'It is surprising how little academic researchers know about the drug development pipeline. This has been very informative and engaging and I would recommend it to students and postdocs.'  - Participant

Industry Fellows are researchers sponsored by industrial partners to undertake collaborative research at the University. There are four Fellowship programs currently running across the Division, supported by Celgene, Novo Nordisk, Elysium and UCB. A recent interview series with these Fellows has revealed the value that many find working with industrial partners.

Celgene Fellow Liliana Cifuentes commented: ‘Working with Celgene as a research fellow has exposed me to a broad range of expertise in industry and has provided valuable access to a scientific network.’ Her comment is echoed by Elysium Fellow Hanlin Zhang: ‘Collaboration with industry is a great way for scientists to translate their discoveries with the help of experts while keeping their own interests in basic science.'

If you are a company interested in supporting fellowships please contact Industry Partnerships Manager Charlotte Bell. 

If you are a researcher interested in becoming a fellow please visit the Business Development Team pages

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.